# AstraZeneca PLC > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/AstraZeneca PLC). ## Overview AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines. Its portfolio spans oncology, rare disease, and biopharmaceuticals including cardiovascular, renal & metabolism, and respiratory & immunology, with products sold in more than 125 countries. ## Products & services • Prescription medicines in oncology • Rare disease therapies • Cardiovascular, renal & metabolism medicines • Respiratory & immunology medicines • Drug discovery and development pipeline • Global commercialisation of approved medicines - **Oncology** (40%) — Cancer medicines and related therapeutic products across multiple tumor types. - **Rare Disease** (10%) — Treatments for uncommon and often specialized patient populations. - **Biopharmaceuticals** (50%) — Medicines for cardiovascular, renal & metabolism, and respiratory & immunology. - Prescription medicines in oncology - Rare disease therapies - Cardiovascular, renal & metabolism medicines - Respiratory & immunology medicines - Drug discovery and development pipeline - Global commercialisation of approved medicines ## Customers AstraZeneca sells primarily to healthcare systems and the institutions that purchase prescription medicines on behalf of patients, including hospitals, clinics, pharmacies, and managed-care or government payers. Its end users are patients with oncology, rare disease, cardiovascular, renal, respiratory, and immunology conditions, but demand is mediated by prescribers and reimbursement systems. The company also interacts with research and clinical-trial ecosystems that support development and adoption of its therapies. - **Hospitals and cancer centers** (primary) — Buy oncology medicines for inpatient, outpatient, and specialty cancer care. - **Government and commercial payers** (primary) — Reimburse medicines and influence access through formulary and coverage decisions. - **Specialty pharmacies** (secondary) — Dispense rare disease and specialty medicines to patients under prescribed care. - **Physicians and specialists** (primary) — Select AstraZeneca brands for patients in oncology and chronic disease areas. - **Patients** (primary) — Use the company’s prescription medicines for treatment of specific diseases. - Hospitals and cancer centers buying oncology therapies - Specialty pharmacies dispensing rare disease treatments - Health systems and payers reimbursing chronic medicines - Physicians and specialists choosing branded prescriptions - Patients using medicines across chronic and acute care ## Geography AstraZeneca is headquartered in Cambridge, UK, and operates as a global business with medicines sold in more than 125 countries. The company’s commercial exposure is geographically diversified across major healthcare markets in North America, Europe, Asia, and other international markets. Its supply, regulatory, and reimbursement profile is therefore shaped by multiple country-specific approval, pricing, and access regimes. - Headquartered in Cambridge, UK - Medicines sold in more than 125 countries - Meaningful exposure to North America and Europe - Global regulatory and reimbursement dependence - International commercial footprint across major markets ## Strategy AstraZeneca’s strategy centers on advancing a broad clinical pipeline and turning research into approved medicines across oncology and specialty care. The company also emphasizes global commercialization of its brands, supported by large-scale clinical development and continued expansion into additional indications and markets. - **Grow oncology and specialty pipeline** (medium-term) — Late-stage assets and new indications drive future branded medicine sales. - **Expand global commercialization** (short-term) — Broader market reach improves uptake of approved medicines across countries. - **Broaden disease-area mix** (medium-term) — A diversified portfolio reduces reliance on any single therapeutic area. - Advance a large late-stage oncology pipeline - Expand approved medicines into new indications - Broaden presence in rare disease and specialty care - Commercialize globally across regulated healthcare markets - Use R&D scale to sustain product innovation ## Risks AstraZeneca faces the classic biopharma risks of clinical trial failure, regulatory setbacks, patent and lifecycle pressure, and payer-driven pricing constraints. The reports also highlight exposure to intangible asset impairments, legal settlements, and foreign exchange movements, all of which can materially affect reported results in a global medicines business. - **Clinical trial and development failure** [high] — The business depends on successful late-stage trials to convert research into revenue-generating products. - **Regulatory approval delays** [high] — Medicines require approvals in each market before sales can expand. - **Pricing and reimbursement pressure** [high] — Payers and governments influence access, price realization, and formulary placement. - **Intangible asset impairment** [high] — Acquisition-related and developed product intangibles can be written down if prospects weaken. - **Legal settlements and contingencies** [medium] — The company discloses settlement and provision exposure that can materially affect earnings. - Clinical development failures can delay or eliminate future launches - Regulatory approval risk can limit access in key markets - Pricing and reimbursement pressure can constrain medicine uptake - Intangible asset impairments and legal settlements affect reported results - Foreign exchange moves can distort comparability across periods ## Accounting AstraZeneca’s reported results are shaped by substantial judgment in acquisition-related intangibles, impairments, legal provisions, and restructuring items. The company also uses core and CER measures that adjust for items such as amortisation of intangibles, impairments, legal settlements, restructuring charges, and foreign exchange, which can materially change the picture versus reported IFRS results. - **Core vs reported measures** — Affects comparability of operating performance versus IFRS reported earnings - **Foreign exchange translation** — Can materially change growth rates and period-to-period comparability - **Intangible assets and impairment** — Influences operating profit and earnings volatility - **Provisions and legal settlements** — Can create large one-off charges and cash outflows - Core vs reported results exclude amortisation, impairments and settlements - CER measures remove foreign exchange effects from comparability - Intangible asset accounting affects earnings and impairment risk - Legal provisions can change materially with new developments - Acquisition-related liabilities may introduce fair value adjustments --- *Last updated: 2026-09-28T11:57:33.338087+00:00*